<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147572</url>
  </required_header>
  <id_info>
    <org_study_id>3122004</org_study_id>
    <nct_id>NCT04147572</nct_id>
  </id_info>
  <brief_title>Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler</brief_title>
  <acronym>TIOPIF</acronym>
  <official_title>Inspiratory Flow Parameters With Placebo Tiotropium Easyhaler® and Placebo Spiriva® Capsule Via HandiHaler® in Patients With COPD and in Healthy Volunteers. Substudy: Easyhaler® and HandiHaler® Usability Study in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will characterise inspiratory flow parameters across placebo dry powder inhaler
      Easyhaler (2 inhaler versions) and placebo Spiriva inhalation powder capsule inhaled via
      HandiHaler in patients with chronic obstructive pulmonary disease (COPD) and in healthy
      volunteers.

      Substudy: Easyhaler® and HandiHaler® Usability study in patients with COPD; to assess
      patients acceptability, preference, correct use and ability to learn to use Easyhaler and
      HandiHaler (with capsules) and to compare PIF rate via In-Check Dial meter with the PIF rate
      via spirometer in the main study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open, randomised, multicentre, crossover study with Easyhaler and HandiHaler
      inhalers. The primary objective is to characterise inspiratory flow parameters across placebo
      dry powder inhaler Easyhaler (2 inhaler versions) and placebo Spiriva inhalation powder
      capsule inhaled via HandiHaler in patients with chronic obstructive pulmonary disease (COPD)
      and in healthy volunteers. The secondary objective is to calculate correlation of peak
      inspiratory flow (PIF) rate with regards to anthropometric and lung function parameters.

      Substudy: This is an open, randomised, multicentre, crossover study with Easyhaler and
      HandiHaler inhalers.There will be 1 study visit per subject, usually this visit is done at
      the same visit with the main study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Actual">January 13, 2020</completion_date>
  <primary_completion_date type="Actual">January 13, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary variable will be the PIF rate through the Easyhaler and HandiHaler inhalers.</measure>
    <time_frame>1 day</time_frame>
    <description>After practising, 3 inspiratory flow curves will be recorded and the inhalation with the highest PIF rate analysed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inspiratory volume through the Easyhaler and HandiHaler inhalers</measure>
    <time_frame>1 day</time_frame>
    <description>Highest inspiratory volume recorded and analysed from the same inhalation as the PIF rate.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correct use of Easyhaler and HandiHaler tabulated by frequencies and percents based on the inhaler specific questionnaire, assessed by the site staff.</measure>
    <time_frame>1 day</time_frame>
    <description>Substudy outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient's acceptability of inhalers, assessed by the study specific questionnaire</measure>
    <time_frame>1 day</time_frame>
    <description>Substudy outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient's preference of inhalers assessed by study specific questionnaire</measure>
    <time_frame>1 day</time_frame>
    <description>Substudy outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient's ability to learn the use of the inhalers, assessed by the study specific questionnaire.</measure>
    <time_frame>1 day</time_frame>
    <description>Substudy outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Peak inspiratory flow measurement via In-Check Dial</measure>
    <time_frame>1 day</time_frame>
    <description>Substudy outcome</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Healthy Volunteer</condition>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Inhaler A, Tiotropium Easyhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo Tiotropium Easyhaler, type A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaler B, Tiotropium Easyhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo Tiotropium Easyhaler, type B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference product, Spiriva modified HandiHaler</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Spiriva, hard capsule inhaled via modified HandiHaler device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy Test product Placebo Tiotropium Easyhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The substudy subjects will demonstrate the use of the inhaler.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy Reference product Placebo Spiriva® HandiHaler</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The substudy subjects will demonstrate the use of the inhaler.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tiotropium inhalation powder type A</intervention_name>
    <description>Placebo inhalation from inhaler A</description>
    <arm_group_label>Inhaler A, Tiotropium Easyhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Spiriva capsule</intervention_name>
    <description>Placebo inhalation from HandiHaler</description>
    <arm_group_label>Reference product, Spiriva modified HandiHaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tiotropium inhalation powder type B</intervention_name>
    <description>Placebo inhalation from inhaler B</description>
    <arm_group_label>Inhaler B, Tiotropium Easyhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Substudy Placebo Tiotropium Easyhaler</intervention_name>
    <description>Substudy placebo inhalation</description>
    <arm_group_label>Substudy Test product Placebo Tiotropium Easyhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Substudy Placebo Spiriva® via HandiHaler</intervention_name>
    <description>Substudy placebo inhalation</description>
    <arm_group_label>Substudy Reference product Placebo Spiriva® HandiHaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for subjects with COPD:

          1. Written informed consent (IC) obtained.

          2. ≥18 years of age.

          3. Documented diagnosis of COPD.

        Inclusion Criteria for healthy volunteers:

          1. Written informed consent (IC) obtained.

          2. ≥18 years of age.

          3. FEV1 at least 80% of the predicted value measured at screening.

          4. Good general health ascertained by medical history.

        Exclusion Criteria for subjects with COPD:

          1. Any chronic respiratory disease other than COPD.

          2. Acute respiratory infection.

          3. Concurrent participation in a clinical drug study.

          4. Any medical condition (e.g. contraindications to spirometry) that in the opinion of
             the investigator could interfere with the interpretation of study results or cause a
             health risk for the subject if he/she participates in the study. E.g. any concomitant
             disease in clinically labile state judged by the investigator.

          5. Severe milk allergy (lactose contains small amounts of milk proteins).

        Exclusion Criteria for healthy volunteers:

          1. Evidence of a clinically significant cardiovascular, renal, hepatic, haematological,
             gastrointestinal, pulmonary, metabolic, endocrine, neurological or psychiatric disease
             within the previous 2 years.

          2. Acute respiratory infection.

          3. Concurrent participation in a clinical drug study.

          4. Any medical condition (e.g. contraindications to spirometry) that in the opinion of
             the investigator could interfere with the interpretation of study results or cause a
             health risk for the subject if he/she participates in the study.

          5. Severe milk allergy (lactose contains small amounts of milk proteins).

        Substudy:

        Patients with documented diagnosis of COPD aged 18 year or older participating the main
        study will be enrolled in this substudy. Written informed consent (IC) will be obtained.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orion Pharma Clinical Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lung Clinic, Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

